Eli Lilly and Merck both reported better-than-expected third-quarter results on the same day, with their share prices rising about 6.6% and 5%, respectively—a strong signal for the traditional pharmaceutical sector.
This has two implications: first, even in a high-interest-rate environment, investors are still willing to pay a premium for reliable earnings and genuine demand; second, market risk appetite has not cooled completely, and better-than-expected results can still quickly drive valuation recoveries.
For crypto markets, this cannot be interpreted directly as good news for Bitcoin or altcoins, but it does suggest that macro risk sentiment is stabilizing somewhat. If U.S. earnings season remains broadly solid, investors may become more tolerant of volatile assets. Conversely, if the crypto sector wants to keep attracting fresh capital, it will ultimately need to deliver real revenue, user growth, and sustainable narratives—not rely solely on sentiment-driven rallies.
In the short term, watch how U.S. tech stocks and expectations for Fed policy affect risk assets.
#美股财报 #宏观流动性 #CryptoMarket
This has two implications: first, even in a high-interest-rate environment, investors are still willing to pay a premium for reliable earnings and genuine demand; second, market risk appetite has not cooled completely, and better-than-expected results can still quickly drive valuation recoveries.
For crypto markets, this cannot be interpreted directly as good news for Bitcoin or altcoins, but it does suggest that macro risk sentiment is stabilizing somewhat. If U.S. earnings season remains broadly solid, investors may become more tolerant of volatile assets. Conversely, if the crypto sector wants to keep attracting fresh capital, it will ultimately need to deliver real revenue, user growth, and sustainable narratives—not rely solely on sentiment-driven rallies.
In the short term, watch how U.S. tech stocks and expectations for Fed policy affect risk assets.
#美股财报 #宏观流动性 #CryptoMarket